Tags

  • Sorting

  • Filters

Thailand cannabis legalization

Thailand has become the first southeast Asian country to legalize cannabis for medical use. Cannabis was originally introduced into Thailand from India, and until it was outlawed in the 1930s, it was historically used as a kitchen condiment, medicine and source of fiber.

Overcoming uncertainty in your PFAS analysis

Overcoming uncertainty in your PFAS analysis

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

6 Signs it’s time for a new vendor

6 Signs it’s time for a new vendor

A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.

Nitrosamines: Where are we now?

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

Why Quant?

Why Quant?

Every decision you make requires a number As a pharmaceutical scientist, you understand the challenges in getting a new drug through the discovery and development pipeline. As an innovation partner in mass spectrometry, SCIEX works continuously with you, our...

Uncovering the Links Between Childhood Growth, Body Size, and a Woman’s Risk of Breast Cancer

Uncovering the Links Between Childhood Growth, Body Size, and a Woman’s Risk of Breast Cancer

Welcome to the second in a series of posts marking International Women’s Day, and our ongoing support of World Cancer Research Fund. This installment is a review by Dr. Jennifer Baker, of her work, that, with the help of a WCRF grant, is studying body size and its links to breast cancer. Dr. Baker, Lead Investigator at Denmark’s Frederiksberg Hospital, has a Ph.D. in Human Nutrition from Cornell University. Her research focuses on clinical epidemiology.

Wordpress Social Share Plugin powered by Ultimatelysocial